IPP Bureau
Bluecrux supports Sanofi in harnessing AI to transform supply chains
By IPP Bureau - May 28, 2024
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
Roche and Hitachi High-Tech extend partnership for further breakthroughs in diagnostic testing
By IPP Bureau - May 28, 2024
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Ascentage releases results from multiple clinical studies of its lead drug candidates
By IPP Bureau - May 28, 2024
These abstracts report on the company's three lead drug candidates, including olverembatinib
AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr
By IPP Bureau - May 28, 2024
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
AstraZeneca furthers ambition to transform outcomes in early lung cancer at ASCO 2024
By IPP Bureau - May 27, 2024
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Alvotech and Dr. Reddy’s collaborate for commercialization of AVT03 (denosumab)
By IPP Bureau - May 27, 2024
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
AbbVie completes acquisition of Landos Biopharma
By IPP Bureau - May 27, 2024
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction
By IPP Bureau - May 27, 2024
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast
By IPP Bureau - May 25, 2024
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Zydus receives final approval from USFDA for Theophylline ER Tablets
By IPP Bureau - May 25, 2024
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
Heuron gets FDA green light for stroke triage and notification solution
By IPP Bureau - May 25, 2024
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Ascentage Pharma releases latest results from multiple clinical studies of lead drug candidates
By IPP Bureau - May 25, 2024
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Swixx Biopharma acquires Biopas to expand in Latin America
By IPP Bureau - May 24, 2024
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
BaseLaunch announces a new partnership with AbbVie
By IPP Bureau - May 24, 2024
Further strengthens BaseLaunch's global pharma industry partnerships
Merck to showcase advances in the science of cancer with new data presented at ASCO 2024
By IPP Bureau - May 24, 2024
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
